云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

休市中 04-02 16:08:21

40.800

+0.200

+0.49%

最高41.940	最低40.000	成交量452.17万
今开40.980	昨收40.600	日振幅4.78%
总市值144.43亿	流通市值144.43亿	总股本3.54亿
成交额1.85亿	换手率1.28%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":40.8,"timestamp":1775117301004,"preClose":40.6,"halted":0,"volume":4521688,"delay":0,"changeRate":0.0049261083743841316,"floatShares":354000000,"shares":354000000,"eps":-1.0128002319876481,"marketStatus":"休市中","change":0.2,"latestTime":"04-02 16:08:21","open":40.98,"high":41.94,"low":40,"amount":185081718,"amplitude":0.047783,"askPrice":40.8,"askSize":2000,"bidPrice":40.78,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-1.060595299115155,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":40.6,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.8381672773473721,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"1154808948","title":"云顶新耀董事长斥资3270万港元 于3月27日以每股38.12港元购入86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1154808948","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154808948?lang=zh_cn&edition=full","pubTime":"2026-03-30 12:18","pubTimestamp":1774844337,"startTime":"0","endTime":"0","summary":"3月27日，云顶新耀董事长在公开市场进行了一次大规模股份增持。根据披露信息，此次交易涉及86万股公司股份，总金额高达3270万港元，每股成交价格为38.12港元。这一举动彰显了公司高层对未来发展的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1583","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623398062","title":"云顶新耀(01952)获主要股东傅唯增持86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623398062","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623398062?lang=zh_cn&edition=full","pubTime":"2026-03-30 12:18","pubTimestamp":1774844307,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀(01952)发布公告，公司董事会获非执行董事、董事会荣誉主席兼公司主要股东傅唯先生告知，于2026年3月27日，傅唯先生透过其控制的公司于市场购入86万股公司普通股，总代价约为3270万港元，平均价格约为每股股份38.12港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀(01952)获主要股东傅唯增持86万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623547361","title":"营收大涨142%，云顶新耀剑指2030年150亿元营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2623547361","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623547361?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:30","pubTimestamp":1774830600,"startTime":"0","endTime":"0","summary":"2025年是“十四五”规划的收官之年，也是中国生物医药行业迈入高质量发展的关键分水岭。得益于多年积累并持续涌现的创新成果、不断加速的研发进展及深化的全球合作，一批具备核心竞争力的创新药企业脱颖而出，云顶新耀（01952.HK）便是其中的典型代表。日前，云顶新耀披露2025年业绩报告显示，全年实现总收入17.07亿元，同比大幅增长142%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603303688161385.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303688161385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622758158","title":"云顶新耀2025年业绩亮眼 管理层详解双轮驱动战略与千亿市值目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2622758158","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622758158?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:49","pubTimestamp":1774622994,"startTime":"0","endTime":"0","summary":"3月26日，港股创新药企云顶新耀（1952.HK）举办2025年度业绩发布媒体沟通会，公司董事会主席吴以芳与首席执行官罗永庆携手亮相，详解全年业绩亮点与未来规划。数据显示，2025年公司实现总收入17.07亿元，同比大增142%；非国际财务准则下首次扭亏为盈，盈利1.87亿元，第四季度经营性现金流回正，现金储备达27.31亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273687502782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01952","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622168918","title":"港股异动 | 云顶新耀(01952)早盘涨超8% 耐赋康销售驱动强劲增长 全年营收大增142%至17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622168918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622168918?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:03","pubTimestamp":1774577020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀早盘涨超8%，截至发稿，涨8.36%，报37.58港元，成交额9885.59万港元。消息面上，云顶新耀发布年度业绩，公司全年营收同比大增142%至17.07亿元，非国际财务准则下首度实现扭亏为盈，录得利润1.87亿元，国际财务准则下亏损亦大幅收窄71%，经营性现金流成功转正。收益增加主要由于耐赋康在已商业化市场的销售额继续上升所致。云顶新耀表示，2026年将成为公司2030年战略的“执行之年”和实现转型的关键之年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155432498","title":"异动解读 | 云顶新耀盘中大涨5.13%，强劲财报及产品管线前景获市场认可","url":"https://stock-news.laohu8.com/highlight/detail?id=1155432498","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155432498?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:48","pubTimestamp":1774576105,"startTime":"0","endTime":"0","summary":"云顶新耀今日盘中股价大涨5.13%，市场表现活跃。消息面上，公司此前公布了2025年度财报并举行了媒体沟通会。财报显示，公司2025年全年总收入达17.07亿元，同比增长142%，并首次在非国际财务报告准则下实现扭亏为盈，净利润为1.87亿元。此外，公司新获批的精氨酸艾曲莫德片（维适平）被寄予厚望，预期峰值销售额可达50亿元。同时，公司计划让依拉环素和精氨酸艾曲莫德片参与国家医保谈判，以提升药品可及性。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622818778","title":"云顶新耀：BD不会一卖了之，两款产品将参与医保谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2622818778","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622818778?lang=zh_cn&edition=full","pubTime":"2026-03-27 08:49","pubTimestamp":1774572540,"startTime":"0","endTime":"0","summary":"“对于BD，我们的态度是，不会‘卖青苗’，而是要找到战略上有协同、能力上能互补、财务上稳健的合作方，帮我们一起共同开发，而不是简单地把它卖掉，这是我们的原则。我们不是一卖了之，我们希望看到长远，能够帮助这些有突破性技术的产品，实现它的长远价值，这是我们最在乎的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686333750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686333750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622198889","title":"云顶新耀(01952)2025年股东净亏损同比收窄71.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622198889","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622198889?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:04","pubTimestamp":1774487064,"startTime":"0","endTime":"0","summary":"金吾财讯 | 云顶新耀(01952)公告发布，截至2025年12月31日止，公司母公司拥有人应占净亏损为2.98亿元(人民币，下同)，同比减亏71.4%，每股基本净亏损0.89元，同比减亏72.5%。期内，录得收益17.07亿元，同比增长1.41倍；毛利润11.82亿元，同比增长1.24倍。期内，集团研发开支5.11亿元，分销及销售开支7.81亿元，一般行政开支2.77亿元。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977287","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622883992","title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883992","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622883992?lang=zh_cn&edition=full","pubTime":"2026-03-26 07:23","pubTimestamp":1774481019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布截至2025年12月31日止年度业绩，集团收益人民币17.07亿元，同比增长141.51%;股东应占亏损2.98亿元;研发开支5.11亿元;毛利11.82亿元，同比增长124.32%。收益增加主要由于耐赋康在已商业化市场的销售额继续上升所致。在中国市场，将耐赋康纳入国家医保药品目录为关键的增长动力，以致截至2025年12月31日止年度的耐赋康收益大幅增加。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1161","BK1574","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166404916","title":"云顶新耀2025年度经营亏损收窄，股东应占亏损同比明显减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1166404916","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166404916?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:58","pubTimestamp":1774479538,"startTime":"0","endTime":"0","summary":"云顶新耀于2025年12月31日止年度录得经营亏损人民币千元613,955，除所得税前亏损人民币千元598,364；本集团权益持有人应占年内亏损为人民币千元297,766，较上一年度的人民币千元1,041,375有所减少。主要管理人员于报告期内的薪酬合计人民币千元130,672，其中包括薪金、津贴及实物利益人民币千元32,828，表现相隔红利人民币千元30,530，以股份为基础的付款开支人民币千元66,212，以及退休金计划供款人民币千元1,102。银行存款为人民币千元887,086，现金及现金等价物则为人民币千元1,779,828。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621005945","title":"港股云顶新耀-B午后涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621005945","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621005945?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:05","pubTimestamp":1774335944,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月24日，云顶新耀-B(01952.HK)午后涨近7%，截至发稿涨6.7%，报34.72港元，成交额7485.13万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682500195.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682500195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4585","01952","BK1574","VXUS","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621566310","title":"港股异动 | 云顶新耀-B(01952)午后涨近7% 公司获得PSVT新药艾曲帕米鼻喷雾剂大中华权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2621566310","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621566310?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:46","pubTimestamp":1774334780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B午后涨近7%，截至发稿，涨6.7%，报34.72港元，成交额7485.13万港元。消息面上，云顶新耀宣布，与箕星药业达成资产收购协议，获得艾曲帕米鼻喷雾剂在大中华区的开发、商业化及产品地产化权益。根据协议，云顶新耀将向箕星药业支付3000万美元首付款，及支付最高不超过2000万美元的开发里程碑付款。在中国，该产品用于治疗PSVT的新药上市申请已于2025年1月获中国国家药品监督管理局正式受理，预计将于2026年第三季度获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","BK1161","01952","BK1583","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621747586","title":"云顶新耀(01952)与箕星药业香港订立资产收购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747586","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621747586?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:04","pubTimestamp":1774224295,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，于2026年3月23日，买方与卖方箕星药业香港订立资产收购协议，买方同意收购而卖方同意出售收购资产，最高代价为5000万美元;及卖方同意向买方出让及转让而买方同意接受卖方出让其根据许可协议及与该出让事项相关的若干附属协议的权利、权益、申索、职责、义务及责任。此外，资产收购协议项下拟进行交易与本集团的整体及长期目标保持一致，从而将以最大程度保障本公司及其股东的长远利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185598210","title":"云顶新耀资产涉及通过鼻腔喷雾装置递送依曲帕米的药品","url":"https://stock-news.laohu8.com/highlight/detail?id=1185598210","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185598210?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:00","pubTimestamp":1774224022,"startTime":"0","endTime":"0","summary":"云顶新耀的核心资产指向了一类利用专用装置、通过鼻腔喷雾方式给药依曲帕米的医药产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620211139","title":"云顶新耀：2亿元定金锁定收购Hasten全部股权，目标公司覆盖东南亚6亿人口市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2620211139","media":"财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620211139?lang=zh_cn&edition=full","pubTime":"2026-03-19 13:14","pubTimestamp":1773897240,"startTime":"0","endTime":"0","summary":"近日，云顶新耀发布公告称，公司与Hasten Biopharmaceuticals  Limited签署了一份意向书，涉及可能收购目标公司Hasten Biopharmaceuticals  Pte. Ltd.的全部股权。根据意向书，云顶新耀将在签署后五个营业日内向卖方支付可退还定金2亿元。此次收购旨在增强公司在亚太地区的业务规模，目标公司在慢病领域拥有14种品牌产品的商业化权益，覆盖约6亿人口的东南亚市场。意向书签署后，卖方将在六个月内不得与其他方讨论相关收购事宜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-19/doc-inhrnzrq0889207.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-19/doc-inhrnzrq0889207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1583","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942031","title":"云顶新耀(01952)可能收购Hasten Biopharmaceuticals (SG) Pte. Ltd.全部股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942031","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620942031?lang=zh_cn&edition=full","pubTime":"2026-03-17 21:11","pubTimestamp":1773753099,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，于2026年3月17日，公司与Hasten Biopharmaceuticals  Limited(卖方)订立一份意向书，内容有关可能收购卖方的全资附属公司Hasten Biopharmaceuticals  Pte. Ltd.的全部股权。目标公司拥有14种慢病领域品牌产品在亚太多个国家和地区的资产权利，包括上市许可持有人权利、商标及广泛的商业化权益。因此，董事认为，可能的收购将补充集团现有的产品管线，并进一步扩大集团在亚太地区的业务规模，从而提升公司股东的回报。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","SG","BK1161","BK1574","01952","BK4209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620141462","title":"港股异动 | 云顶新耀-B(01952)早盘涨近5% 眼科新药VIS-101计划下半年启动IIb期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2620141462","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620141462?lang=zh_cn&edition=full","pubTime":"2026-03-17 10:56","pubTimestamp":1773716215,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B早盘涨近5%，截至发稿，涨4.11%，报37.96港元，成交额4956.24万港元。消息面上，3月13日，云顶新耀宣布，其在研眼科管线VIS-101治疗湿性年龄相关性黄斑变性的IIa期研究取得积极顶线数据。基于此次IIa期积极的临床数据，VIS-101计划于2026年下半年启动IIb期临床研究，并于2027年启动全球III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","VXUS","BK1161","BK4588","BK4585","01952","VIS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619965371","title":"每日卖空追踪 | 云顶新耀 03月13日卖空量成交7.8万股，卖空比例为7.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619965371","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619965371?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:30","pubTimestamp":1773390626,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间03月13日，跌2.11%，卖空量成交7.8万股，较上一交易日减少45.64%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313163352a4663e98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313163352a4663e98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619196325","title":"云顶新耀03月13日遭主力抛售183.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619196325","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619196325?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:16","pubTimestamp":1773389761,"startTime":"0","endTime":"0","summary":"03月13日, 云顶新耀股价跌2.11%，报收36.10元，成交金额4024.5万元，换手率0.31%，振幅2.66%，量比0.48。云顶新耀今日主力资金净流出183.5万元，上一交易日主力净流出151.1万元。该股近5个交易日下跌1.96%，主力资金累计净流出427.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出419.7万元，其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313162137a46633a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313162137a46633a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618911282","title":"每日卖空追踪 | 云顶新耀 03月10日卖空量成交8.3万股，卖空比例为3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618911282","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618911282?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131426,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间03月10日，涨4.66%，卖空量成交8.3万股，较上一交易日减少69.54%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163324a45df77c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163324a45df77c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":0.1765},{"period":"1month","weight":0.2043},{"period":"3month","weight":0.0765},{"period":"6month","weight":-0.2772},{"period":"1year","weight":-0.2817},{"period":"ytd","weight":0.1033}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.064726},{"month":5,"riseRate":0.4,"avgChangeRate":-0.02945},{"month":6,"riseRate":0.8,"avgChangeRate":0.307082},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114966},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}